▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights has been a contributing writer and analyst for The Motley Fool since 2012. Prior to The Motley Fool, Speights was CEO of a healthcare technology company; vice president of a healthcare software company; director of operations for a health insurer; and a technology consultant. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

Joe Biden - US Dept of State Flickr

Jan 20, 2021 by Keith Speights

3 Unbeatable Stocks to Buy for a Biden Bull Market

Each of them should win in different ways with Joe Biden in the White House.

Thumbs up from businessman

Jan 19, 2021 by Keith Speights

Why Gilead Sciences Stock Is Jumping Today

A Wall Street analyst upgraded the biotech stock.

Cannabis with chart going up

Jan 19, 2021 by Keith Speights

Meet the Marijuana Stock That's Already Doubled in 2021

Could it have even more room to run?

Vaccine bottles forming a dollar sign

Jan 19, 2021 by Keith Speights

Moderna CEO's 9 Words That Could Mean Billions for the Biotech

We just have to wait to find out if he's right.

Dollar sign on top of graph

Jan 18, 2021 by Keith Speights

These 3 Under-the-Radar Stocks Are Great Buys Right Now

You might not hear much about them, but that could be a good thing.

Telehealth - female doctor and patient

Jan 17, 2021 by Keith Speights

3 Telemedicine Stocks You Can Buy Right Now

Two are telemedicine leaders already, and one could be on its way to becoming a major player.

Solar panels, wind turbines

Jan 17, 2021 by Keith Speights

My Best Dividend Stock for 2021

There's a lot to like with this high-flying dividend stock.

3 arrows on target with dollar sign

Jan 17, 2021 by Keith Speights

3 Popular Robinhood Stocks That Should Make You Richer in 2021

The future looks bright for these Robinhood investor favorites.

Older woman about to get vaccine

Jan 16, 2021 by Keith Speights

Why the U.S. Is Running Behind With COVID-19 Vaccinations

There are multiple reasons.

Picking vaccine bottle

Jan 16, 2021 by Keith Speights

Why Novavax Could Become a Latecomer Leader in the COVID Vaccine Race

This small biotech could be like the tortoise in Aesop's famous fable.

Light bulb with vaccine

Jan 16, 2021 by Keith Speights

3 Fantastic Coronavirus Vaccine Stocks to Buy Right Now

Each has more to offer than just a COVID-19 vaccine.

Red line pointing down

Jan 15, 2021 by Keith Speights

Why Cardiff Oncology Stock Is Crashing Today

The biotech presented data from an early-stage study of its experimental colorectal cancer drug.

Hepatitis B syringe

Jan 15, 2021 by Keith Speights

Why VBI Vaccines Stock Is Vaulting Higher Today

The company reported good news from a study of its hepatitis B vaccine.

Joe Biden - US Dept of State Flickr

Jan 15, 2021 by Keith Speights

What Might Biden Do Differently With COVID Vaccine Rollouts?

More money could be on the way.

Smiling Warren Buffett - TMF

Jan 15, 2021 by Keith Speights

This Is the Best COVID Vaccine Stock Based on Warren Buffett's Investing Rules

Really only one of the legendary investor's rules are needed.

2 COVID vaccines in front of $100

Jan 15, 2021 by Keith Speights

Better Buy: Novavax vs. Moderna

Both of these biotechs could be big winners in the COVID-19 vaccine market.

Question mark with stock chart

Jan 15, 2021 by Keith Speights

Is Pfizer Stock a Buy?

Don't focus on the big drugmaker's past. Look to the future.

Digital portrait of young woman with dollar signs

Jan 15, 2021 by Keith Speights

3 Fantastic Growth Stocks That Could Set You Up for Life

Seriously, they could.

Dry eyes written on chalkboard

Jan 14, 2021 by Keith Speights

Why Aldeyra Therapeutics Stock Is Jumping Today

The company announced the pricing of a public stock offering.

Doctor with vaccine syringe and question mark

Jan 14, 2021 by Keith Speights

Will the New Coronavirus Strain Affect Vaccines' Efficacy?

There's good news.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services